In 2023, net loss for the fourth quarter and year ended December 31, 2023, was $20.1 million and
$40.8 million, respectively. In 2022, the net loss for the fourth quarter was $6.0 million and $17.1 million for the full year.
On
December 31, 2023, XOMA had cash and cash equivalents of $159.6 million (including $6.3 million in restricted cash). In 2023, XOMAs royalty interests generated cash payments of $7.3 million from Roche related to VABYSMO® sales and $1.7 million from Medexus related to IXINITY® sales. The Company also received a $5.0 million milestone payment from
Viracta related to the FDAs acceptance of Day One Pharmaceuticals NDA for tovorafenib. These cash receipts from royalty and milestone acquisitions reduced XOMAs short-term royalty and commercial payment receivables by
$14 million. On October 16, 2023, the Company paid total cash dividends of $1.4 million on the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) and on the 8.375% Series B Cumulative Perpetual Preferred Stock
(Nasdaq: XOMAO). In December 2023, XOMA drew $130.0 million from its royalty-backed loan with certain funds managed by the credit platform of Blue Owl Capital. On December 31, 2022, the Company reported cash of $57.8 million. Based
upon the cash flows XOMA expects to receive from VABYSMO®, DSUVIA®, and
IXINITY® sales in addition to its current cash position, the Company continues to believe its current cash position will be sufficient to fund XOMAs operations for multiple years.
Subsequent Events
On January 2, 2024, the Company
announced a stock repurchase program of up to $50 million through January 2027.
On January 7, 2024, Owen Hughes was appointed as Chief
Executive Officer and Jack Wyszomierski was named Chairman of the Board of Directors.
On January 18, 2024, XOMA acquired an economic interest in
DSUVIA® (sufentanil sublingual tablet) from Talphera, Inc., for $8 million. DSUVIA® is commercialized by Alora Pharmaceuticals.
XOMA will receive 100 percent of all royalties and milestones related to DSUVIA® sales until it receives $20 million. Thereafter, XOMA will receive a 15 percent royalty
associated with DSUVIA® commercial sales, a 37.5 percent royalty on DoD purchases and 50 percent of the remaining $116.5 million in potential milestone payments due from Alora
Pharmaceuticals.
On February 16, 2024, XOMA announced its intention to acquire Kinnate Biopharma for between $2.3352 and $2.5879 in cash per share
plus a contingent value right (CVR). XOMA anticipates it will add approximately $9.5 million to its cash balance at the closing of the acquisition, which is expected to occur in April 2024.
About XOMA Corporation
XOMA is a biotechnology royalty
aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial and commercial
therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive,
non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to
receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.